The review paper, Regorafenib for the Treatment of Sarcoma, was recently published in Current Treatment Options in Oncology, 23 (11):1477-1502 (2022).

We are pleased to share a snapshot of the paper in this video from Prof. Robert Maki, along with accompanying slides and an infographic summary of the findings.

Physicians face challenges in selecting the most appropriate and effective treatments for sarcomas. In this paper, experts summarise the unmet needs of this patient group and review the current trial data to examine the safety profile and clinical activity of regorafenib in sarcoma subtypes.

 

Clinical takeaways:

  • Regorafenib demonstrated benefit in patients with osteosarcoma, Ewing sarcoma and non-adipocytic soft tissue sarcomas who had progressed on prior therapy
  • Patients who have otherwise limited treatment options may benefit from regorafenib therapy

Dr Maki is a medical oncologist who has focused for over 20 years to understand tumors arising from connective tissues, which include sarcomas and other aggressive tumors that do not metastasize, such as desmoid tumors. These tumors represent less than 1% of all cancers that happen in adults. I work with patients with these diagnoses to find the right treatment for the 70 or more types of bone and soft tissue sarcomas and other soft tissue tumors. As part of this work, I also reserach new medications for cancer in general, a field called developmental therapeutics. In my research, I seek to find new medications that may be useful for sarcoma patients, and try to figure out why they work or not. I work closely with colleagues at Penn Medicine, the Children's Hospital of Philadelphia, and with other national and international teams of researchers such as SARC, the Sarcoma Alliance for Research through Collaboration, to improve the understanding and treatment of sarcomas.

Prof. Robert Maki has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

 American Society for Clinical Oncology,  Bayer, Deciphera, Kayopharm, Peel Therapeutics and Tracon.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
SARCOMA CONNECT

SARCOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Karyopharm Therapeutics.

Meet the experts

Other programmes of interest

podcast Podcast
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Sep 2024

video Video
Oncology Hemato-oncology 
Early relapsed/refractory multiple myeloma (RRMM): best practices in management

A 3-part video series on managing early RRMM from leading medical experts

Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2024

other Other

Episode

2

of 2

episode
Oncology 
Optimising samples for biomarker testing in lung, prostate and gastric cancer

Recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Aug 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
publication Publication
Oncology 
Advancing HCC management in Asia: insights from patients and HCPs

Paper published in Journal of Gastrointestinal Cancer

Experts
Prof. Chee-Kiat Tan
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Jul 2024

This educational programme is supported by an Independent Educational Grant from Roche.
other Other
Oncology 
Come and visit us in Barcelona at ESMO 2024!

Get your free professional profile photos taken with us at Booth 507

  • clock 1 MIN
  • calendar Jul 2024

micro-learning Micro learning
Oncology Endocrinology Rare diseases 
Tools for optimising treatment & management of advanced NETs

Maximising outcomes for patients with advanced neuroendocrine tumours 

Experts
Prof. Emily Bergsland, Prof. Louis de Mestier
Endorsed by
NANETS
Neuroendocrine Cancer UK
CommNETs
The Healing NET Foundation
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Educational Grant from Ipsen.